Key Points: Mechanistic modeling of stable isotope labeling verifies human neutrophil half-lives of 13-19 h in contrast to recent estimates of >3 days. Human neutrophil kinetics can be measured using a single-dose deuterium-labeled glucose protocol.
1 February 2015 in Drug Metabolism and Disposition
In recent years, many new designer drugs have emerged, including the group of cathinone derivatives. One frequently occurring is mephedrone, that although was originally considered as "legal high" product, is currently banned in most Western countries. Despite the banning, abuse of the drug and seizures are continuously reported. Although the metabolism of mephedrone has been studied in rats or in vitro using human liver microsomes, to the best of our knowledge, no dedicated study with human volunteers has been performed for studying the in vivo metabolism of mephedrone in humans. So, the aim of this study was to establish the actual human metabolism of mephedrone and to compare it with other models. For this purpose, urine samples of two healthy volunteers, who ingested 200 mg of mephedrone by orally, were taken before administration and 4 hours after substance intake. The discovery and identification of the Phase I and Phase II metabolites of mephedrone was based on ultra-performance liquid chromatography coupled to hybrid quadrupole-time of flight mass spectrometry (UHPLC-QTOF MS), operating in the so-called MSE mode. Six phase I metabolites and four phase II metabolites were identified, four of them not previously reported in the literature. The structure of four of the detected metabolites has been confirmed by synthesis of the suggested compounds. Remarkably, a mephedrone metabolite conjugated with succinic acid has been identified and confirmed by synthesis. According to the reviewed literature, this is the first time that this type of conjugate is reported for human metabolism.
In vivo [6,6-2H2]-glucose labelling is a state of the art technique for quantifying cell proliferation and cell disappearance in humans. However, there are discrepancies between estimates of T cell proliferation reported in short (one-day) versus long (seven-day) 2H2-glucose studies and very-long (9-week) 2H2O studies. It has been suggested that these discrepancies arise from underestimation of true glucose exposure from intermittent blood sampling in the one-day study. Label availability in glucose studies is normally approximated by a “square pulse”. Since the body glucose pool is small and turns over rapidly the availability of labelled glucose can be subject to large fluctuations and the square pulse approximation may be very inaccurate. Here we model the pharmacokinetics of exogenous labelled glucose using a physiologically based pharmacokinetic (PBPK) model to assess the impact of a more complete description of label availability as a function of time on estimates of CD4+ and CD8+ T cell proliferation and disappearance. The model enabled us to predict the exposure to labelled glucose during the fasting and de-labelling phases, capture the fluctuations of labelled glucose availability caused by the intake of food or high-glucose beverages, and to re-calculate the proliferation and death rates of immune cells. The PBPK model was used to reanalyse experimental data from three previously published studies using different labelling protocols. Although using the PBPK enrichment profile decreased the one-day proliferation estimates by about 4% and 7% for CD4 and CD8+ T cells, respectively, differences with the seven-day and 9-week studies remained significant. We conclude that the approximations underlying the “square pulse” approach – recently suggested as the most plausible hypothesis– only explain a component of the discrepancy in published T cell proliferation rate estimates.